The global anti-obesity drugs market size was valued at USD 2.77 Billion in 2025, with Latin America holding a significant market share. It is expected to grow at a CAGR of 10.70% during the forecast period of 2026-2035. The market is poised to secure a value of USD 7.66 Billionby 2035, driven by the rising prevalence of obesity among children and teenagers across the region.
Base Year
Historical Period
Forecast Period
According to the report released by the United Nations, Overview of Food Security and Nutrition 2022, almost one-fourth (22.5%) of the Latin American population is unable to afford a healthy meal in comparison to the world approximately priced at USD 3.89 per person per day.
The increasing prevalence of obesity due to the adaption of a sedentary lifestyle along with unhealthy dietary habits are significant factors driving the Latin America anti-obesity drugs market growth in the forecast period.
The regional market is witnessing high incidence of anti-obesity drugs, which is likely to boost the market share in the forecast period. In February 2023, Tesofensine received positive opinions from Mexican Food and Drug Administration.
Compound Annual Growth Rate
10.7%
Value in USD Billion
2026-2035
*this image is indicative*
Obesity is a growing problem globally and is significantly contributing to high rates of health issues. Therefore, battling this condition is a major necessity of the hour. The Latin American region is facing major health issues related to obesity among children, teenagers, and adults. In August 2023, UNICEF released a report which highlighted that more than 4 million children aged 5 years or less were overweight in Latin American and Caribbean region.
Latin America anti-obesity drugs market share is estimated to be influenced by the approval of drugs by regional regulatory authorities. For instance, in December 2019, Medix, a Mexican pharmaceutical company submitted a New Drug Application (NDA) to the Mexican Food and Drug Administration COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) for the approval of tesofensine (a monoamine uptake inhibitor), which can be used for treating obesity in patients. Tesofensine has demonstrated effective loss results in phase II studies in obese patients. After a long wait, on February 26, 2023, the tesofensine was provided a favourable opinion by the Mexican regulatory authority for the treatment of obese patients. Considering the efficacy provided by tesofensine in the clinical trial, a potential interest from both healthcare providers and patients is anticipated, propelling the market growth. The competitive landscape is also expected to be driven by the approval of tesofensine.
Latin America anti-obesity drugs market demand is likely to be propelled by the alarmingly increasing obesity rates. It has been highlighted that the current prevalence rate in Latin America is above the global average, and it has been rising over the last two decades at a sustained rate. Additionally, it contributes to various other health concerns such as hypertension, high cholesterol, diabetes, cardiovascular disease, and even cancer. Addressing obesity among people at early stages is a major precaution that can play a crucial role in timely treatments and overall increased the life expectancy of obese population in the region.
The market report offers a detailed analysis of the market based on the following segments:
Breakup by Drugs
Breakup by Drug Class
Breakup by Mechanism of Action
Breakup by Route of Administration
Breakup by Prescription Type
Breakup by Distribution Channel
Breakup by Region
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Upto 15% Off
USD
$2699 $2429
$4299 $3869
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The Latin America anti-obesity drugs market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 10.70% during the forecast period of 2026-2035, to reach a market value of USD 7.66 Billion by 2035.
Major factors aiding the market demand include the increasing prevalence of obesity along with diabetes mellitus among all age groups.
One of the significant trends in the market is the increasing research and development activities and regulatory approvals to reduce the number of obese patients in the region. For instance, the approval of tesofensine by Mexican regulatory authorities for the treatment of obese patients.
Based on drugs, the market is segmented into Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, and Tirzepatide.
It includes amphetamines, GLP-1 receptor agonists, and lipase inhibitors.
Mechanisms of action include centrally acting drugs and peripherally acting drugs.
Route of administration includes oral and subcutaneous.
Type of prescriptions include prescription drugs and over-the-counter drugs.
Based on distribution channels, the market is segmented into hospital pharmacies, drug store & retail pharmacies, and online pharmacies.
The market segmentation by countries includes Brazil, Argentina, Mexico, and others
The key players in the market are and VIVUS Inc., Nalpropion Pharmaceuticals Inc., Pfizer, Inc., Novo Nordisk, Bayer AG, F Hoffmann-La-Roche, GlaxoSmithKline, Arena Pharmaceuticals, Eisai Co. Ltd, Takeda Pharmaceutical Company.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drugs |
|
| Breakup by Drug Class |
|
| Breakup by Mechanism of Action |
|
| Breakup by Route of Administration |
|
| Breakup by Prescription Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share